Gan & Lee(SH:603087) 生物世界·2026-03-03 00:15Core Viewpoint - Obesity is a chronic and progressive disease that poses significant public health challenges globally, with a sharp increase in prevalence since 1975, affecting over 2.5 billion adults worldwide, including 34.8% of Chinese adults classified as overweight and 14.1% as obese [2][3]. Group 1: Obesity and Its Implications - The clinical consequences of obesity are severe, being a recognized risk factor for multiple complications such as insulin resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, and metabolic dysfunction-related fatty liver disease [2]. - There is an urgent need for effective and sustainable interventions to control obesity and its related complications [2]. Group 2: Treatment Advances - The foundation of weight management remains comprehensive lifestyle interventions, including dietary adjustments, increased physical activity, and behavioral therapy, although achieving and maintaining clinically significant weight loss through these methods can be challenging [5]. - Recent advancements in pharmacological treatments for obesity, particularly with the development of GLP-1 receptor agonists, have shown significant weight loss effects and various beneficial multi-faceted effects, including improved blood glucose control, reduced blood pressure, and improved lipid profiles [5]. Group 3: Bofanglutide Clinical Trials - Bofanglutide, a long-acting GLP-1 receptor agonist developed by Ganli Pharmaceutical, has a pharmacokinetic profile that allows for bi-weekly dosing, showing promise as a potential treatment option for weight management and type 2 diabetes [6]. - In a phase 2b clinical trial involving overweight or obese adults in China, Bofanglutide demonstrated good overall tolerability and significant weight loss, with participants losing between 9.75% to 16.69% of their body weight over 30 weeks compared to a mere 1.15% in the placebo group [8][10]. - The trial included 340 participants, with a majority completing the study, and highlighted the need for less frequent dosing to improve treatment adherence and sustainability [8][10]. Group 4: Safety and Efficacy - The study indicated that Bofanglutide treatment resulted in a dose-dependent reduction in weight and significant improvements in cardiovascular metabolic risk factors, with manageable safety profiles even at higher doses [10]. - The findings support the further development of Bofanglutide as a bi-weekly administered formulation for effective weight management [10].